Altered cerebral hemodynamics in early Alzheimer disease: a pilot study using transcranial Doppler. by Claassen, J.A.H.R. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a postprint version which may differ from the publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/79954
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
1Altered Cerebral Hemodynamics in Early Alzheimer Disease: a Pilot Study using 
Transcranial Doppler.
Jurgen A.H.R. Claassen, MD PhD; Ramon Diaz-Arrastia, MD PhD; Kristin Martin-Cook 
MSc; Benjamin D. Levine, MD; Rong Zhang, PhD
Department of Geriatric Medicine, Radboud University Nijmegen Medical Center (JC). 
Department of Neurology (RDA, KMC) and Internal Medicine (BL, RZ), University of 
Texas Southwestern Medical Center, Dallas, TX. Institute for Exercise and 
Environmental Medicine, Presbyterian Hospital, Dallas, TX (JC, BL, RZ)
Correspondence:
Rong Zhang, PhD
Institute for Exercise and Environmental Medicine,
Presbyterian Hospital of Dallas,
7232 Greenville Avenue, Dallas, TX, 75231.
Phone: 214-345-8843 
Fax: 214-345-4618
rongzhang@texashealth.org
Word count: 4.780 (total) 2.707 (text only)
1
2Abstract
Introduction. Cerebrovascular disease may contribute to the development and 
progression of Alzheimer’s disease (AD). This study investigated whether impairments 
in cerebral hemodynamics can be detected in early-stage AD.
Methods. 9 patients with mild AD and 8 cognitively normal controls matched for age 
underwent brain MRI and neuropsychological evaluation, followed by assessment of 
steady-state cerebral blood flow velocity (CBFV, transcranial Doppler), blood pressure 
(BP, Finapres) and cerebrovascular resistance index (BP/CBFV). Cerebral 
hemodynamics were quantified using spectral and transfer function analysis of BP and 
CBFV in rest, during standing up after squat, and during repeated squat-stand 
maneuvers.
Results. Compared with controls, Alzheimer patients had lower CBFV and higher 
cerebrovascular resistance index, unexplained by brain atrophy. Low-frequency 
variability of BP was enhanced, suggesting impaired arterial baroreflex function. 
However, CBFV variability was reduced despite enhanced BP variability, and dynamic 
cerebral autoregulation was not impaired.
Conclusion. Despite a distinct pattern of altered cerebral hemodynamics, AD patients 
may have normal autoregulation. However, the challenges for autoregulation in AD are 
higher, as our data show enhanced BP fluctuations. Increased cerebral vasoconstriction 
or reduced vasomotion also may attenuate CBFV variability.
Key Words: Alzheimer Disease; Cardiovascular Physiology; Cerebral Autoregulation; 
Transcranial Doppler ultrasonography
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3Introduction
Vascular pathology plays an important role in the development and progression of 
Alzheimer’s disease (AD) [1-6]. Vascular risk factors increase the risk of developing AD
[7]. Brain autopsy studies have observed that both large and small-vessel disease are 
extensively present in AD [1,8]. In animal models of AD, these changes led to impaired 
cerebral autoregulation - the vascular mechanisms to maintain cerebral perfusion - 
thereby increasing the risk of brain ischemia [9]. However, at present it remains 
unknown whether cerebral autoregulation is also impaired in human AD. This of 
particular relevance as there is preliminary evidence which suggests that blood 
pressure (BP) regulation may be affected in AD [10,11], for example manifested as a 
reduced baroreflex function [12].
Transcranial Doppler ultrasonography (TCD) allows measurements of cerebral blood 
flow velocity (CBFV) in the major cerebral arteries. Registered together with BP, 
synchronized data of beat-to-beat variability in BP and CBFV are obtained, and transfer 
function analysis, a method based on spectral analysis of beat-to-beat data, can then be 
used to quantify dynamic cerebral autoregulation [13,14]. In this pilot study, we used 
this method to assess BP regulation and dynamic cerebral autoregulation in patients 
with early AD.
Materials and Methods
3
4Subjects
After having screened 11 patients and 12 controls, we included 9 patients with a 
diagnosis of probable AD according to NINCDS-ADRDA criteria, with a clinical dementia 
rating scale of 0.5 (n=3) or 1.0 (n=6), and 8 controls, matched for age and level of 
education, recruited from the Alzheimer Disease Center at UT Southwestern Medical 
Center, Dallas. Subjects with acute or chronic knee or hip conditions which would 
prevent them from performing squat-stand maneuvers (2 controls) and subjects without 
an adequate acoustic window, preventing high quality TCD signal detection (1 control, 1 
AD) were excluded during the initial screening process. Subsequently, 2 subjects (1 
control, 1 AD) were excluded because of poor finger BP and TCD signal quality during 
measurements. The study was approved by the Institutional Review Boards of the 
University of Texas Southwestern Medical Center and Presbyterian Hospital of Dallas. 
All participants signed an informed consent form. In AD patients, additional informed 
consent was obtained by proxy. AD patients and their controls underwent a 
comprehensive clinical-neuropsychological evaluation and brain imaging using MRI. 
Characteristics of the study participants are listed in Table 1.
Cerebral autoregulation
The brain can adapt cerebrovascular resistance in response to changes in BP to 
maintain a relatively stable CBF [14,15]. Static autoregulation refers to the stability of 
CBF within a certain range of BP values that fall within the upper and lower limits of 
autoregulation [15]. This concept however is based on BP and CBF measurements 
averaged over at least several minutes. Recent methods allow the measurement of
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5changes in CBF to more rapid (seconds) changes in BP to reflect rapid adaptation of 
the cerebral vasculature. This concept is known as dynamic cerebral autoregulation
[14].
Hemodynamic Measurements
All measurements were performed at the same time of day (morning), in the same quiet 
laboratory with constant ambient temperature.
BP was measured in the finger by photoplethysmography (Finapres, Ohmeda, 
Englewood, CO), a validated method for hemodynamic research [16].
The hand with the Finapres cuff was held steadily in place at heart level, with the arm 
supported by straps attached to a custom-designed vest, and the hand fixed against the 
chest with a Velcro glove. CBFV was obtained in the middle cerebral artery (MCA) on 
one side by transcranial Doppler ultrasonography (DWL Elektronische Systeme, 
Germany) [13]. End-tidal CO2 was monitored with a nasal cannula using capnography 
(Criticare Systems, Inc., Waukesha, WI). In addition, peripheral arterial saturation 
(pulse-oximetry) and 3-lead ECG were recorded.
After at least 10 min rest in sitting position, 5-min segments of BP and CBFV data were 
recorded during spontaneous respiration. To quantify dynamic cerebral autoregulation, 
these data were used for spectral analysis of spontaneous oscillations in BP and CBFV. 
This method is known as transfer function analysis of spontaneous oscillations in BP 
and CBFV [13].
To enhance the magnitude of alterations in BP and CBF -  and to mimic such changes 
in daily life associated with changes in body posture- oscillations in BP and CBFV were
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6induced by repeated squat-stand maneuvers [17]. After careful instruction and practice, 
participants were coached into performing these maneuvers at a frequency of 0.025 Hz 
(20 s squat followed by 20 s standing up) for 5 min, 0.05 Hz (10 s squat, 10 s stand) for 
4 min and at 0.1 Hz (5 s squat, 5 s stand) for 3 min, separated by 10 min of recovery. 
Physical assistance during standing up from squat was provided to aid the performance 
of these maneuvers, and patients and controls were provided auditory support by a 
metronome as well as verbal instruction to maintain precise rhythm of the maneuvers. 
Alzheimer patients had their caregiver present in the laboratory during all tests, and 
were constantly monitored by a research nurse and a geriatrician. Neither patients nor 
controls showed signs of stress or anxiety before, during or after testing.
Transfer Function Analysis of Dynamic Cerebral Autoregulation
The method of transfer function analysis, which provides the parameters of gain, phase
and coherence, has been described in detail previously [13].
Transfer gain quantifies how the amplitudes of the changes (oscillations) in BP at 
different frequencies are transmitted to CBFV; a lower gain implies that these 
oscillations are reduced (damped) either by dynamic cerebral autoregulation or 
increases in the cerebrovascular impedance [18].
Transfer function phase reflects the time relationship between oscillations in BP and 
CBFV. Coherence can be compared to a linear correlation coefficient, and quantifies to 
what extent changes in CBFV are linearly associated with changes in BP.
MRI Measurements
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T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) images were obtained 
using a Philips Intera 1.5T scanner. Images were converted from DICOM to ANALYZE 
format to facilitate analysis. Segmentation of skull and connective tissue was conducted 
using the skull strip function in the DICOM image editor MRIcro. White matter lesion 
volume and whole brain volume were measured using an image processing tool 
developed with MATLAB (The MathWorks, Inc., Natick, MA) [19].
Standing Up Following a Single Squat
To investigate the effect of a single hypotensive challenge to cerebral perfusion, we 
measured the hemodynamic effects of a single squat (60 s) followed by standing up in 5 
aging controls and 6 AD patients.
Statistical Analysis
Comparisons were made between AD and healthy aging. For normally distributed data, 
two-tailed Student t-test was used. Not all data resulting from transfer function analysis 
were normally distributed. Here, Student t-test was repeated after log-transformation of 
the data, and in addition non-parametric testing was used (Wilcoxon rank test). Linear 
regression analysis was used to explore the relationship between BP and CBFV 
spectral power. Statistical significance was defined as p < 0.05. Data are presented as 
mean and standard deviation (SD).
Results
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8Patient Characteristics
Alzheimer patients had relatively mild cognitive deficits consistent with early stage of the 
disease (Table 1), but were clearly impaired in episodic memory. As expected due to 
the diagnostic criteria for probable AD, patients had no overt cerebrovascular disease 
on MRI. However, volumetric analysis revealed a trend towards more white matter 
lesions in AD. Whole brain volume was not significantly different.
Baseline hemodynamics are presented in Table 2. Despite the early stage of disease, 
AD patients had a substantially lower CBFV and higher cerebrovascular resistance 
compared with the controls.
Cerebral Hemodynamics
Figure 1 shows an example of spontaneous oscillations in BP and CBFV, as well as the 
oscillations that were induced by repeated squat-stand maneuvers, in one patient with 
AD and one control subject. Note that oscillations are larger in AD for BP, but smaller 
for CBFV, compared to the healthy control.
Figure 2 displays the results of spectral analysis of oscillations in BP and CBFV. Note 
the larger spectral power in AD for BP oscillations, but not for CBFV.
The relationship between BP and CBFV spectral power, for spontaneous as well as for 
induced oscillations, is plotted in figure 3. Compared with healthy controls, patients with 
AD display a low CBFV spectral power relative to higher BP spectral power, both for 
spontaneous oscillations and for oscillations induced by the repeated squat-stand 
maneuvers. In other words, in AD, larger variability in BP was associated with reduced, 
rather than increased, variability in CBFV.
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9Group mean values for BP and CBFV spectral power are presented in Table 3. 
Individual differences in the magnitude of BP oscillations could not be explained by a 
higher or lower baseline BP, nor by a history of hypertension.
Estimates of transfer function gain, phase and coherence are depicted in figure 4. 
Transfer function gain for induced oscillations at the frequencies of 0.05 and 0.1 Hz was 
reduced by ~ 30 % in AD relative to normal controls (p= 0.01). However, for 
spontaneous oscillations this difference was not significant (p = 0.18).
The reduction in mean BP upon standing up after a single squat was slightly larger (39 
mm Hg (SD 16)) in AD than in controls (26 mm Hg (SD 11)), or in relative change, a 
reduction of 33 vs. 26 % (p = 0.2). The orthostatic BP reduction following squat led to a 
reduction in mean CBFV of 12 (SD 4) vs. 21 (SD 26) cm/s in AD vs. controls, or 26 and 
29 % (p=0.77). However, AD patients reached lower diastolic flow-velocity values 
during standing (12 (SD 7) vs. 24 (SD 11) cm/s, p = 0.02).
Discussion
With non-invasive monitoring of blood pressure and cerebral blood flow-velocity using 
TCD, we observed a distinct pattern of changes in cerebral hemodynamics in patients 
with mild Alzheimer’s disease. However, dynamic cerebral autoregulation was not 
impaired. In summary, the observed alterations consisted of a reduced CBFV with 
elevated cerebrovascular resistance, not explained by brain atrophy; and reduced 
CBFV oscillations, despite increases in oscillations in BP, suggesting cerebral
9
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vasoconstriction. Although enhanced damping of flow oscillations occurs in AD, CBFV 
especially diastolic CBFV, was profoundly reduced during transient orthostatic 
hypotension. This suggests that autoregulation in AD may fail to compensate for the 
globally reduced cerebral blood flow and instability of blood pressure leading to brain 
hypoperfusion under orthostatic stress.
Reduced CBFV in AD
Baseline CBFV was reduced by 40 % in AD compared with age-matched 
controls, coupled with a 40% increase in cerebrovascular resistance. Although we 
measured CBFV only in the MCA (providing blood flow to ~ 70% of the brain), our study 
is consistent with findings of a reduction in total CBF of ~ 20 % early in the disease 
process of AD [20,21]. It has been argued that reduction in CBF in AD could be 
explained by brain atrophy or by a reduction in brain metabolic demand [22]. However, 
differences in individual whole brain volume between our AD patients and their controls 
could not explain their differences in CBFV (Table 1 and 2), suggesting that changes in 
CBF were not related exclusively to brain atrophy [21,23]. In addition, a reduction in 
brain metabolic demand in the mild stage of AD (CDR 0.5 - 1) is not likely to explain a 
40 % reduction in CBF under resting conditions [20].
Enhanced BP Oscillations with reduced CBFV oscillations in AD
The finding of increased oscillations in BP, combined with reduced oscillations 
in CBFV, in patients with AD was unexpected, and has not been reported previously.
BP oscillations in the very low frequency range (between 0.02 and 0.07 Hz) are
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characterized by periods of 14 - 50 s, which translate into intervals of spontaneously 
elevated BP that last ~ 7 -  25 s, alternated with intervals of reduced BP of that same 
approximate length. The high BP spectral power in AD patients signifies the magnitude 
of these changes in BP (Table 3). In this study, we cannot determine the cause of these 
enhanced oscillations. Most likely, these data indicate that in early AD, alterations occur 
in BP regulation which may be related to the central impairment of baroreflex function
[12]. The right insular region has an important role in the regulation of autonomic 
function [10,11]. As this region is affected by Alzheimer neuropathology early in the 
course of disease, it has been suggested that AD may be associated with autonomic 
dysfunction in baroreflex control of arterial pressure [11]. In a similar vein, pathology of 
the insula and amygdala has been implicated in central autonomic disturbances 
including sudden cardiac death [10].
Oscillations in CBFV were reduced in AD. This finding is striking considering that, 
because of the stronger oscillations in BP, oscillations in CBFV were expected to be 
stronger, not weaker, in AD. This may be explained by enhanced cerebral 
vasoconstriction or vascular deformation that have been linked with AD, such as 
arteriolar luminal obstruction, microvascular deformation or endothelial dysfunction 
associated with amyloid ß [3-6,24]. This interpretation may bear implications for studies 
using functional magnetic resonance imaging (fMRI) in AD. FMRI measures neuronal 
activity indirectly through the blood oxygen level dependent (BOLD) hemodynamic 
response function. It is interesting to note that the amplitude of this hemodynamic 
response is reduced in early AD during brain activation [25]. Although this is usually 
taken to represent altered neural activity and/or neurovascular coupling, in the light of
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the present study it may well be driven primarily by the increases in vascular resistance 
or impedance in AD.
Dynamic Cerebral Autoregulation in AD
This is the first study to assess dynamic cerebral autoregulation in patients with 
AD (previous human studies have investigated vasomotor reactivity to CO2 but not 
pressure autoregulation). Dynamic autoregulation reduces the impact on CBF of slow 
(low frequency) changes in BP, but becomes progressively ineffective for more rapid 
changes in BP (high frequency), consistent with a "high-pass filter”. Consequently, 
reduction in transfer function gain (and increase in phase) at lower frequencies of BP 
oscillations is interpreted as normal autoregulation [14]. According to this model, 
dynamic autoregulation was not impaired in AD, as this would have resulted in an 
increased rather than decreased transfer function gain, as well as reductions in phase. 
This is in contrast with the findings in an AD animal model where cerebral 
autoregulation was impaired even before vascular deposition of amyloid ß had occurred
[9]. However, direct comparisons between studies in humans and animals may be 
difficult. In addition, only static, not dynamic autoregulation was assessed in animal 
studies [9].
The lower gain (reduced CBFV oscillations) in AD may suggest that cerebral 
vasoconstrictive and/or vasodilatory responses to changes in BP were enhanced, thus 
leading to reductions in CBFV variability. This interpretation, however, is not supported 
by the observations during orthostatic hypotension (induced by the single squat-stand 
maneuver), where it was clear that cerebral autoregulation could not prevent a
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substantial and prolonged reduction in CBFV in AD. We therefore conclude that the 
reduced transfer function gain in AD most likely reflects increased cerebrovascular 
resistance and/or impedance associated with cerebral vasoconstriction. This is 
consistent with recent findings of increased cerebrovascular resistance and reduced 
cerebrovascular compliance in AD using perfusion MRI [21].
The reduction in gain in AD was significant only for the squat-stand maneuvers. Most 
likely, this is because gain calculations are statistically more reliable as the signal to 
noise ratio is improved due to the much larger and more coherent oscillations in BP and 
CBFV [17].
Study Limitations
Certain limitations of this study need to be addressed. First, this is an explorative 
study in a small number of subjects. Second, AD patients were treated with the 
cholinesterase-inhibitor donepezil and the NMDA-receptor antagonist memantine, and 
there is evidence to suggest that cholinesterase-inhibitors may augment CBF and 
improve neurovascular function [26]. This could mean that the deleterious 
neurovascular effects of AD have been underestimated in this study. Third, some 
patients and controls were hypertensive or used antihypertensive drugs. Previous 
research has shown that neither mild to moderate hypertension per se, or the use of 
antihypertensive medication, affects dynamic cerebral autoregulation [18]. Furthermore, 
exclusion of these patients would seriously hamper the generalizability of this study. 
Finally, the methodological caveats of using TCD to estimate changes in cerebral blood 
flow have been discussed in detail before [14].
13
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Conclusion
Patients with early AD had a distinct pattern of altered cerebral hemodynamics including 
reduced cerebral blood flow velocity and increased cerebral vascular resistance.
Induced BP fluctuations such as might be encountered during daily life were markedly 
exaggerated, consistent with impaired baroreflex function. Although these BP 
fluctuations induced smaller changes in cerebral blood flow velocity in AD patients 
(consistent with either improved dynamic autoregulation or increased cerebrovascular 
impedance), cerebral blood flow was severely compromised during orthostatic stress, 
demonstrating reduced vasomotor reserve in patients with AD.
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Table 1. Characteristics of the Study Participants
Characteristic Alzheimer’s Disease 
(N= 9)
Aging Controls 
(N= 8)
P Value
Age-yrs 67.9 (5.5) 64.5 (4.0) 0.17
Gender -male:female 3:6 4:4
MMSE 25 (3.2) 29 (0.5) 0.03
Word list recall- no. of words 2 (1.9) 8 (1.3) 0.0001
Paragraph recall- sentences 1 (2.1) 18 (3.9) 0.0001
TMT-A- T score 40 (18) 58 (15) 0.068
TMT-B- T score 40 (11) 59 (10) 0.014
CDR- sum of boxes 4 (1.2) 0.1 (0.2) 0.0001
Total brain volume-ml 1081 (65) 1108 (79) 0.53
White matter lesions-ml 14 (10.4) 8 (5.8) 0.25
Vascular risk factors (no. of subjects)
Hypertension 4 3
Diabetes 0 0
Smoking 0 0
Medication
Antihypertensive drugs 4 3
lipid-lowering drugs 4 2
cholinesterase-inhibitor 8 -
NMDA-receptor antagonist 8 -
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MMSE: Mini mental state examination. TMT: trail making test (parts A and B) CDR: 
Clinical dementia rating scale
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Table 2. Baseline Hemodynamic Parameters
Alzheimer’s Disease 
(N= 9)
Aging Controls 
(N= 8)
P Value
Systolic blood pressure-mmHg 140 (19.8) 126 (26.5) 0.23
Diastolic blood pressure-mmHg 74 (9.0) 73 (9.8) 0.91
Mean arterial pressure-mmHg 101 (12.4) 95 (15.8) 0.39
Mean arterial pressure-mmHg
(from Finapres)
98 (12.4) 94 (10.9) 0.39
Cerebral blood flow-velocity-cm/s 38 (7.1) 55 (19.0) 0.05
Cerebrovascular resistance-
mmHg/cm/s
2.7 (0.7) 1.9 (0.6) 0.03
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Table 3. Spectral Power of Spontaneous and Induced Oscillations in Blood 
Pressure and Cerebral Blood Flow Velocity.
Alzheimer’s Disease Aging Controls P Value
Spontaneous oscillations N=9 N=8
PS BP - mmHg2
VLF 9.6 (5.5) 5.6 (2.4) 0.08
LF 2.4 (1.4) 2.6 (3.1) 0.84
HF 0.5 (0.6) 0.6 (0.5) 0.69
PS CBFV -  (cm/s)2
VLF 3.0 (1.7) 5.5 (5.1) 0.18
LF 1.5 (1.4) 2.8 (4.2) 0.43
HF 0.4 (0.5) 0.5 (0.4) 0.68
Induced oscillations at 0.025 Hz N=4 N=4
PS BP - mmHg2 239 (150.6) 86.3 (67.3) 0.11
PS CBFV - (cm/s)2 11.8 (7.3) 39.5 (42.9) 0.27
Induced oscillations at 0.05 Hz N= 9 N=8
PS BP - mmHg2 460.9 (185.4) 306.8 (131.2) 0.06
PS CBFV - (cm/s)2 84.3 (55.5) 149.6 (109.1) 0.16
Induced oscillations at 0.1 Hz N=9 N=8
20
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PS BP - mmHg2 315 (117.8) 195.3 (90.8) 0.03
PS CBFV - (cm/s)2 77.8 (45.4) 126 (58.5) 0.08
BP: blood pressure. CBFV: cerebral blood flow-velocity. PS: power spectrum, indicating 
the magnitude of the observed oscillations within the specified frequency range. VLF: 
very low frequency oscillations, 0.02 -  0.07 Hz. LF: low frequency, 0.07-0.2 Hz. HF: 
high frequency, 0.2-0.35 Hz. Spontaneous oscillations were recorded during five 
minutes of rest in sitting position. Induced oscillations were provoked by repeated squat- 
stand maneuvers at 20/20, 10/10 and 5/5 s intervals (0.025, 0.05 and 0.1 Hz 
respectively).
21
22
Titles and Legends to Figures
Figure 1. Spontaneous and induced oscillations in blood pressure and cerebral blood 
flow velocity. Example from two representative subjects, one with AD and one normal 
control, demonstrating spontaneous oscillations in blood pressure and cerebral blood 
flow-velocity over a period of 5 min (panel A). Panel B through D depict the effect of 
repeated squat-stand maneuvers at different intervals on these oscillations. Recording 
periods are 5, 4 and 3 min respectively. Panel B shows how repeated squat-stand 
intervals at 20 s lead to oscillations at 0.025 Hz. Panel C: 10 s intervals with oscillations 
at 0.05 Hz. Panel D: 5 s intervals with oscillations at 0.1 Hz.
Figure 2. Spectral density plots of oscillations in blood pressure and cerebral blood flow 
velocity. Individual power spectral density plots for aged controls and Alzheimer 
patients, for blood pressure (upper pane) and cerebral blood flow-velocity (lower pane). 
Spectral power is a measure indicating the strength of oscillations at the specified 
frequency. The Y-axis shows the magnitude of the observed oscillations, and the X -  
axis displays the frequency of these oscillations. Note the much stronger oscillations in 
blood pressure in the very low frequency range (0.02 -  0.07 Hz) in Alzheimer patients, 
with reduced oscillations in cerebral blood flow-velocity.
Figure 3. Correlation between spectral power of blood pressure (PSBP) and cerebral 
blood flow velocity (PSCBFV). A: spontaneous oscillations during rest. B: 
oscillations induced by repeated squat-stand maneuvers at 0.025, 0.05 and 0.1 Hz. 
For each individual, PSBP is plotted against PSCBFV. ■ : Alzheimer patients. •  : 
normal controls. Filled symbols: very low frequency (0.02 -  0.07 Hz, A) and 0.025
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and 0.05 Hz maneuvers (B), half-filled symbols: low frequency (0.07-0.2 Hz, A) and
0.1 Hz maneuvers (B), open symbols: high frequency (0.2 -0.35 Hz, A). The 
correlation between PSBP and PSCBFV (p < 0.05) is less strong in AD patients 
than in controls. In addition, the slope of the regression lines differs between 
patients and controls (A: 1.18 vs. 0.23, B: 0.39 vs. 0.11, p = 0.01 ), indicating lower 
PSCBFV relative to PSBP in Alzheimer patients.
Figure 4. Transfer function analysis of spontaneous and induced oscillations in blood 
pressure and cerebral blood flow velocity. Group-averaged data showing results of 
transfer function analysis of spontaneous oscillations (left) in blood pressure (BP) and 
cerebral blood flow-velocity (CBFV) as well as of oscillations induced by repeated 
squat-stand maneuvers (right). ■: Alzheimer patients. •: normal controls. *: p < 0.05; ** 
p < 0.01. N= 9 (Alzheimer patients) resp. 8 (controls) for spontaneous oscillations and 
maneuvers at 0.05 and 0.1 Hz; n= 4 for maneuvers at 0.025 Hz.
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Figure 1. Spontaneous and Induced Oscillations in Blood Pressure and Cerebral 
Blood Flow Velocity
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Figure 2. Spectral Density Plots of Oscillations in Blood Pressure and Cerebral 
Blood Flow Velocity
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Figure 3. Correlation Between Spectral Power of Blood Pressure and Cerebral 
Blood Flow Velocity.
BP spectral power (mmHg2)
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Figure 4 Transfer Function Analysis of Spontaneous and Induced Oscillations in 
Blood Pressure and Cerebral Blood Flow Velocity
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